Carmat ready to resume the implantations of its artificial heart, the title jumps | Photo credits: Carmat
PARIS, Sept 15 (Reuters) – Carmat confirmed on Thursday that it is preparing to resume implanting its Aeson artificial heart in October, subject to obtaining the necessary authorizations.
In a press release, the French company said it was counting on “strong demand” and “sustained dynamics of post-recovery establishments”.
On the Paris Stock Exchange, the action takes 6.24% to 13.62 euros, against a gain of 0.23% for the CAC 40 to GMT.
Carmat had carried out a “voluntary, temporary” suspension of implantations last December due to quality problems with some of its medical devices.
The group claims to have produced “new prostheses incorporating modifications intended to avoid the quality problems incurred in the past” to meet demand after the resumption of implantations. (Written by Myriam Rivet and Claude Chendjou, edited by Nicolas Delame)